TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.
News  ›  GlobeNewswire Inc.

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

GlobeNewswire Inc. Logo GlobeNewswire Inc. • •By Faruqi & Faruqi, Llp
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Skye Bioscience

Law firm Faruqi & Faruqi is investigating potential securities fraud claims against Skye Bioscience following the company's announcement that its drug nimacimab failed to meet primary endpoints in a Phase 2a clinical trial. The disclosure of lower-than-expected drug exposure and failure to achieve weight loss compared to placebo resulted in a 60% stock price decline on October 6, 2025. Investors who purchased securities between November 4, 2024 and October 3, 2025 are encouraged to contact the firm, with a January 16, 2026 deadline to seek lead plaintiff status.

Insights
MRSN   neutral

Being acquired at $25 per share with potential additional milestone payments, representing a strategic exit for the company

SKYE   negative

The company faces securities litigation alleging false and misleading statements about its drug candidate nimacimab's effectiveness. The clinical trial failure resulted in a 60% stock price drop, and executives are accused of overstating the drug's clinical, regulatory, and commercial prospects.

Keywords
#securities fraud #class action lawsuit #clinical trial failure #nimacimab #stock price decline #lead plaintiff #drug development

Tickers
SKYE
← Prev: Colgate Looks Mispriced as Value, Yield, and Buybacks Start to Line Up